{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T12:11:04Z","timestamp":1772539864395,"version":"3.50.1"},"reference-count":45,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:00:00Z","timestamp":1750377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Medical University of Silesia","award":["BNW-1-042\/N\/3\/K"],"award-info":[{"award-number":["BNW-1-042\/N\/3\/K"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["ARM"],"abstract":"<jats:p>Background: Severe asthma is associated with significant morbidity and risk of complications. Some patients, suffering from eosinophilic asthma, may benefit from biological therapies, especially anti IL-5 (anti-interleukin-5). The purpose of the study was to compare the efficacy evaluation of mepolizumab and benralizumab in the treatment of eosinophilic asthma. Methods: A retrospective, single-centre study including 59 patients with severe eosinophilic asthma treated with biologics (mepolizumab and benralizumab). Clinical outcomes, including peripheral blood morphotic characteristics, spirometry parameters, asthma control questionnaire (ACQ), mini-Asthma Quality of Life Questionnaire (mini-AQLQ) scores, daily oral corticosteroid use, body mass index, exacerbation rate, and exercise tolerance, were examined at the beginning and after 6 months of biological treatment. Results: A total of 38 patients were treated with mepolizumab and 21 with benralizumab. Significant improvements (p &lt; 0.05) in eosinophil count, required daily dose of glucocorticoids, ACQ, mini-AQLQ scores, and exacerbation rate were observed in both groups after six months of treatment. There was no statistical difference (p &lt; 0.05) in the abovementioned parameters between the groups. Conclusions: In patients with severe eosinophilic asthma, mepolizumab and benralizumab were associated with significant improvements in clinical state. Patients with type 2 asthma will benefit from the therapy with both anti-IL5 biologic drugs.<\/jats:p>","DOI":"10.3390\/arm93040021","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T11:23:24Z","timestamp":1750418604000},"page":"21","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The Comparative Effectiveness of Mepolizumab and Benralizumab in the Treatment of Eosinophilic Asthma"],"prefix":"10.3390","volume":"93","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8644-4048","authenticated-orcid":false,"given":"Aleksandra","family":"Niemiec-G\u00f3rska","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Allergology and Clinical Immunology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 40-752 Katowice, Poland"},{"name":"Doctoral School, Medical University of Silesia, 40-752 Katowice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2464-8923","authenticated-orcid":false,"given":"Olga","family":"Branicka","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Allergology and Clinical Immunology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 40-752 Katowice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Olszewska","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Allergology and Clinical Immunology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 40-752 Katowice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4228-9343","authenticated-orcid":false,"given":"Sylwia","family":"Mielcarska","sequence":"additional","affiliation":[{"name":"Doctoral School, Medical University of Silesia, 40-752 Katowice, Poland"},{"name":"Department of Medical and Molecular Biology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 40-752 Katowice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6339-9053","authenticated-orcid":false,"given":"Joanna","family":"Gl\u00fcck","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Allergology and Clinical Immunology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 40-752 Katowice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9653-0801","authenticated-orcid":false,"given":"Barbara","family":"Rymarczyk","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Allergology and Clinical Immunology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 40-752 Katowice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rados\u0142aw","family":"Gawlik","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Allergology and Clinical Immunology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 40-752 Katowice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,6,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.jaip.2017.05.001","article-title":"Asthma Exacerbations: Pathogenesis, Prevention, and Treatment","volume":"5","author":"Castillo","year":"2017","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13223-020-00507-0","article-title":"Targeting the IL-5 Pathway in Eosinophilic Asthma: A Comparison of Mepolizumab to Benralizumab in the Reduction of Peripheral Eosinophil Counts","volume":"17","author":"Ghassemian","year":"2021","journal-title":"Allergy Asthma Clin. Immunol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1164\/rccm.200903-0392OC","article-title":"T-Helper Type 2\u2013Driven Inflammation Defines Major Subphenotypes of Asthma","volume":"180","author":"Woodruff","year":"2009","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Maspero, J., Adir, Y., Al-Ahmad, M., Celis-Preciado, C.A., Colodenco, F.D., Giavina-Bianchi, P., Lababidi, H., Ledanois, O., Mahoub, B., and Perng, D.W. (2022). Type 2 Inflammation in Asthma and Other Airway Diseases. ERJ Open Res., 8.","DOI":"10.1183\/23120541.00576-2021"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.anai.2019.10.016","article-title":"Asthma Biologics: Comparing Trial Designs, Patient Cohorts and Study Results","volume":"124","author":"Doroudchi","year":"2020","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.anai.2018.07.029","article-title":"Use of Biomarkers to Identify Phenotypes and Endotypes of Severe Asthma","volume":"121","author":"Carr","year":"2018","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.jaci.2023.06.005","article-title":"Eosinophils and Tissue Remodeling: Relevance to Airway Disease","volume":"152","author":"Siddiqui","year":"2023","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/j.jaci.2017.10.005","article-title":"Biomarkers of Severe Eosinophilic Asthma","volume":"140","author":"Yancey","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.iac.2015.05.007","article-title":"Novel Therapies for Eosinophilic Disorders","volume":"35","author":"Bochner","year":"2015","journal-title":"Immunol. Allergy Clin. N. Am."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Scioscia, G., Nolasco, S., Campisi, R., Maria, C., Quarato, I., Caruso, C., Pelaia, C., Portacci, A., and Crimi, C. (2023). Switching Biological Therapies in Severe Asthma. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24119563"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1164\/rccm.201810-1944CI","article-title":"Role of Biologics in Asthma","volume":"199","author":"McGregor","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e20221212","DOI":"10.1084\/jem.20221212","article-title":"Th2 Responses Type 2 Inflammation and Biological Therapies in Asthma: Targeted Medicine Taking Flight","volume":"220","author":"Howell","year":"2023","journal-title":"J. Exp. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"26","DOI":"10.12703\/r\/11-26","article-title":"Recent Advances in Understanding the Role of Eosinophils","volume":"11","author":"Constantine","year":"2022","journal-title":"Fac. Rev."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1080\/02770903.2022.2139718","article-title":"Cost-Effectiveness of Benralizumab versus Mepolizumab and Dupilumab in Patients with Severe Uncontrolled Eosinophilic Asthma in Spain","volume":"60","author":"Mareque","year":"2023","journal-title":"J. Asthma"},{"key":"ref_15","first-page":"1193","article-title":"A Cost Comparison of Benralizumab, Mepolizumab, and Dupilumab in Patients with Severe Asthma: A US Third-Party Payer Perspective","volume":"29","author":"Xu","year":"2023","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"ref_16","unstructured":"Ministerstwo Zdrowia (2024, July 23). Programy Lekowe, Available online: https:\/\/archiwum.mz.gov.pl\/leki\/refundacja\/programy-lekowe\/."},{"key":"ref_17","unstructured":"European Medicines Agency (2024, November 06). Annex I Summary of Product Characteristics. European Medicines Agency, Nucala European Public. Assessment Report. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/nucala."},{"key":"ref_18","unstructured":"European Medicines Agency (2024, November 06). Annex I Summary of Product Characteristics. European Medicines Agency, Fasenra European Public Assessment Report. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/fasenra."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1034\/j.1399-3003.1999.14d29.x","article-title":"Development and Validation of a Questionnaire to Measure Asthma Control","volume":"14","author":"Juniper","year":"1999","journal-title":"Eur. Respir. J."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1034\/j.1399-3003.1999.14a08.x","article-title":"Development and Validation of the Mini Asthma Quality of Life Questionnaire","volume":"14","author":"Juniper","year":"1999","journal-title":"Eur. Respir. J."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"03000605221133689","DOI":"10.1177\/03000605221133689","article-title":"Comparison between Clinical Trials and Real-World Evidence Studies on Biologics for Severe Asthma","volume":"50","author":"Menzella","year":"2022","journal-title":"J. Int. Med. Res."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Kayser, M.Z., Suhling, H., Fuge, J., Hinze, C.A., Drick, N., Kneidinger, N., Behr, J., Taube, C., Welte, T., and Haasler, I. (2024). Long-Term Multicenter Comparison Shows Equivalent Efficacy of Monoclonal Antibodies in Severe Asthma Therapy. BMC Pulm. Med., 24.","DOI":"10.1186\/s12890-024-02964-4"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Bolk, K.G., and Wise, S.K. (2024). Biologic Therapies across Nasal Polyp Subtypes. J. Pers. Med., 14.","DOI":"10.3390\/jpm14040432"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1016\/j.jaip.2022.02.034","article-title":"Comparison of Different Biologics for Treating Chronic Rhinosinusitis with Nasal Polyps: A Network Analysis","volume":"10","author":"Cai","year":"2022","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.jaci.2021.08.030","article-title":"Efficacy and Safety of Benralizumab in Chronic Rhinosinusitis with Nasal Polyps: A Randomized, Placebo-Controlled Trial","volume":"149","author":"Bachert","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Chiner, E., Murcia, M., Boira, I., Bernabeu, M.\u00c1., Esteban, V., and Mart\u00ednez-Morag\u00f3n, E. (2024). Real-Life Clinical Outcomes of Benralizumab Treatment in Patients with Uncontrolled Severe Asthma and Coexisting Chronic Rhinosinusitis with Nasal Polyposis. J. Clin. Med., 13.","DOI":"10.20944\/preprints202407.0402.v1"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S2213-2600(21)00097-7","article-title":"Mepolizumab for Chronic Rhinosinusitis with Nasal Polyps (SYNAPSE): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial","volume":"9","author":"Han","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1016\/j.clinthera.2017.09.011","article-title":"Long-Term Systemic Corticosteroid Exposure: A Systematic Literature Review","volume":"39","author":"Rice","year":"2017","journal-title":"Clin. Ther."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1111\/all.12438","article-title":"Osteoporosis in the At-Risk Asthmatic","volume":"69","author":"Aljubran","year":"2014","journal-title":"Allergy Eur. J. Allergy Clin. Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"619","DOI":"10.2147\/DDDT.S155307","article-title":"Benralizumab in the Treatment of Severe Asthma: Design, Development and Potential Place in Therapy","volume":"12","author":"Pelaia","year":"2018","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.jaci.2022.05.024","article-title":"Comparative Efficacy of Mepolizumab, Benralizumab, and Dupilumab in Eosinophilic Asthma: A Bayesian Network Meta-Analysis","volume":"150","author":"Akenroye","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"212580","DOI":"10.7573\/dic.212580","article-title":"Efficacy and Steroid-Sparing Effect of Benralizumab: Has It an Advantage over Its Competitors?","volume":"8","author":"Menzella","year":"2019","journal-title":"Drugs Context"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jaci.2018.08.031","article-title":"Anti-IL-5 Treatments in Patients with Severe Asthma by Blood Eosinophil Thresholds: Indirect Treatment Comparison","volume":"143","author":"Busse","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"863","DOI":"10.2147\/JAA.S319572","article-title":"Real-World Multicenter Experience with Mepolizumab and Benralizumab in the Treatment of Uncontrolled Severe Eosinophilic Asthma Over 12 Months","volume":"14","author":"Kayser","year":"2021","journal-title":"J. Asthma Allergy"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/cea.12853","article-title":"Comparison of Anti-Interleukin-5 Therapies in Patients with Severe Asthma: Global and Indirect Meta-Analyses of Randomized Placebo-Controlled Trials","volume":"47","author":"Cabon","year":"2017","journal-title":"Clin. Exp. Allergy"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1801393","DOI":"10.1183\/13993003.01393-2018","article-title":"Matching-Adjusted Indirect Comparison of Benralizumab versus Interleukin-5 Inhibitors for the Treatment of Severe Asthma: A Systematic Review","volume":"52","author":"Bourdin","year":"2018","journal-title":"Eur. Respir. J."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Vitale, C., Maglio, A., Pelaia, C., D\u2019Amato, M., Ciampo, L., Pelaia, G., Molino, A., and Vatrella, A. (2023). Effectiveness of Benralizumab in OCS-Dependent Severe Asthma: The Impact of 2 Years of Therapy in a Real-Life Setting. J. Clin. Med., 12.","DOI":"10.3390\/jcm12030985"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1080\/08923973.2023.2300300","article-title":"Eosinophil to Lymphocyte Ratio May Predict OCS Reduction and Change in Quality of Life (AQLQ) Resulting from Asthma Biological Treatment","volume":"46","author":"Branicka","year":"2024","journal-title":"Immunopharmacol. Immunotoxicol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1159\/000509116","article-title":"Eosinophil\/Neutrophil\/Platelet-to-Lymphocyte Ratios in Various Types of Immediate Hypersensitivity to NSAIDs: A Preliminary Study","volume":"181","author":"Branicka","year":"2020","journal-title":"Int. Arch. Allergy Immunol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1111\/resp.14578","article-title":"Benralizumab and Mepolizumab Treatment Outcomes in Two Severe Asthma Clinics","volume":"28","author":"Langton","year":"2023","journal-title":"Respirology"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"00341","DOI":"10.1183\/23120541.00341-2022","article-title":"The Impact of Anti-Eosinophilic Therapy on Exercise Capacity and Inspiratory Muscle Strength in Patients with Severe Asthma","volume":"9","author":"Franceschi","year":"2023","journal-title":"ERJ Open Res."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Kvarnstr\u00f6m, K., Westerholm, A., Airaksinen, M., and Liira, H. (2021). Factors Contributing to Medication Adherence in Patients with a Chronic Condition: A Scoping Review of Qualitative Research. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13071100"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.therap.2018.11.001","article-title":"The Limitations of Observation Studies for Decision Making Regarding Drugs Efficacy and Safety","volume":"74","author":"Gueyffier","year":"2019","journal-title":"Therapies"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"398","DOI":"10.4997\/jrcpe.2020.409","article-title":"Retrospective Studies\u2014Utility and Caveats","volume":"50","author":"Talari","year":"2020","journal-title":"J. R. Coll. Physicians Edinb."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11882-017-0686-1","article-title":"Mechanisms Driving Gender Differences in Asthma","volume":"17","author":"Fuseini","year":"2017","journal-title":"Curr. Allergy Asthma Rep."}],"container-title":["Advances in Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2543-6031\/93\/4\/21\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:55:57Z","timestamp":1760032557000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2543-6031\/93\/4\/21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,20]]},"references-count":45,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["arm93040021"],"URL":"https:\/\/doi.org\/10.3390\/arm93040021","relation":{},"ISSN":["2543-6031"],"issn-type":[{"value":"2543-6031","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,20]]}}}